Bayer AG 's pharma CEO Dieter Weinand said during the firm's R&D day on Dec. 1 that the company had not revised its peak sales estimate of more than $1bn for its radiopharmaceutical product Xofigo after new safety concerns led to a Phase III trial being unblinded early, despite the fact it was testing the product in a larger population than that for which it is already approved.
Bayer Shrugs Off Xofigo Sales Pressure From Study Halt
Amid turmoil at Bayer's R&D unit, the company revealed that a Phase III trial of Xofigo had thrown up a safety issue for the product. Bayer insists peaks sales will be unaffected, but what had been a large potential new patient population now looks unlikely.
